Cambridge Cognition Holdings PLC Launch of web-based testing for virtual research

TIDMCOG

Cambridge Cognition Holdings PLC

07 March 2017

07 March 2017

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Cambridge Cognition launches web-based testing for virtual research

The global neuroscience digital health company Cambridge Cognition Holdings PLC (Cambridge, UK - LSE: COG), which develops and markets software products to improve brain health, today announces the launch of a new web-based testing product for conducting academic and clinical research studies online.

Disorders affecting the brain are now the leading cause of disability and ill health worldwide. More than 1,000 disorders of the brain and central nervous system (CNS) result in huge costs, more hospitalisations and loss of productivity than any other disease group, including heart disease and cancer(1) .

Advances in research will improve this outlook but administrative costs, inadequate research tools and limited access to patient populations can slow progress.

To support neuroscience research, CANTAB Connect, the worlds most validated cognitive assessment software now enables researchers to assess participants on a global scale, in a quick and cost-effective manner.

Cambridge Cognition's CANTAB(R) technology has been used to measure cognitive function in leading academic and industry research for over 30 years. The Company now markets a range of digital health products on mobile and wearable devices to help recruit participants into clinical trials, validate treatment efficacy and monitor brain health in daily life.

Web-based testing is the latest innovation, empowering researchers to run near-patient testing of participants remotely. The innovation will allow studies to gather digital cognitive biomarkers at frequent time-points for more accurate and rapid data to aid earlier decision-making and conduct large-scale research projects virtually, reducing the overall running costs of studies using proven neuropsychological assessments.

Dr Steven Powell, Chief Executive Officer, Cambridge Cognition, commented: "The increasing prevalence of neurological and psychiatric disorders including depression, Parkinson's and Alzheimer's disease has resulted in a growing need for innovative neuroscience digital health tools. Web-based testing using CANTAB Connect is a key part of our strategy to provide scientifically proven products to assist researchers and healthcare professionals in improving brain health worldwide."

For information about web-based cognitive testing:

Visit: www.cantab.com/connect

Watch: https://www.youtube.com/watch?v=JbkX98xkkb8

(1) Society for Neuroscience. https://www.sfn.org/about/about-neuroscience [last accessed 20 February 2017]

Notes to editors

About Cambridge Cognition Holdings PLC

Cambridge Cognition is a neuroscience digital health company specialising in the precise measurement of clinical outcomes in neurological disorders. The Company develops and markets validated in-patient assessment software products to improve understanding, diagnosis and treatment in global brain health.

www.cambridgecognition.com

Enquiries

 
 Cambridge Cognition Holdings PLC 
  Steven Powell, Chief Executive          Tel: [phone] 
  Officer                                 700 
  Noah Konig, Director of Marketing       [e-mail] 
  and Communications 
 finnCap Ltd (NOMAD and Joint Broker)   Tel: [phone] 
  Geoff Nash / Simon Hicks               0500 
  Alice Lane                             (Corporate Finance) 
                                         (Corporate Broking) 
 Dowgate Capital Stockbrokers Limited   Tel: [phone] 
  (Joint Broker)                         744 
  David Poutney / James Serjeant 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAFMGGFNVKGNZM

(END) Dow Jones Newswires

March 07, 2017 02:02 ET (07:02 GMT)